FDA approves Octapharma USA’s IND application to begin trial with severe Covid-19 patients

Octapharma USA has secured approval from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application to begin a phase three clinical trial to assess the efficacy and safety of Octagam 10% [Immune Globulin Intravenous (Human)] therapy in Covid-19 patients with severe disease progression.